Table 4 Previous reports of efficacy of PEG-G-CSF
No. | Author | Year | Primary Tumor | Regimen | Patients number | Major outcomes |
|---|---|---|---|---|---|---|
1 | Yamao et al. [16] | 2019 | PC | mFOLFIRINOX | 45 | PFS (prolonged) |
2 | Xie et al. [17] | 2018 | BC | EC, TC, ET | 569 | Incidence and duration of grade 3/4 neutropenia |
3 | Pinter et al. [18] | 2017 | CRC | FOLFOX, FOLFIRI | 845 | Incidence of grade 3/4 FN in the first 4 cycles |
4 | Kubo et al. [19] | 2016 | ML | CHASE(R) | 111 | Duration of severe neutropenia |
5 | Lee et al. [20] | 2016 | BC | TAC | 60 | Duration of grade 4 neutropenia in cycle 1 |
6 | Blackwell et al. [21] | 2016 | BC | TAC | 308 | Duration of severe neutropenia during cycle 1 |
7 | Harbeck et al. [22] | 2016 | BC | TAC | 316 | Duration of severe neutropenia during cycle 1 |
8 | Zhang et al. [23] | 2015 | BC | TAC | 171 | Incidence of grade 3/4 neutropenia |
9 | Kosaka et al. [24] | 2015 | BC | TC | 351 | Incidence of FN |
10 | Bozzoli et al. [25] | 2015 | DLBCL | RCHOP | 51 | Frequency of FN and unplanned hospitalizations |
11 | Gladkov et al. [26] | 2015 | BC | Doxorubicin/Docetaxel | 78 | Incidence of adverse events |
12 | Shi et al. [27] | 2013 | BC, NSCLC, NHL, HNC | PC, AC, CHOP | 337 | Rate of protection against grade 4 neutropenia |
13 | Hecht et al. [28] | 2010 | CRC | FOLFOX, FOLFIRI, FOIL | 241 | Incidence of grade 3/4 neutropenia. |
14 | Fox et al. [29] | 2009 | Sarcoma | VDC, IE | 34 | Duration of severe neutropenia |
15 | Sierra et al. [30] | 2008 | AML | Idarubicin/cytarabine | 84 | Assisting neutrophil recovery |
16 | von Minckwitz et al. [31] | 2008 | BC | TAC | 1256 | Primary prophylaxis of FN and related toxic effects |
17 | Bladucci et al. [32] | 2007 | Solid tumors or NHL | Carboplatin, Cisplatin, Doxorubicin, Doxorubicin and Paclitaxel, AC, Docetaxel, ACT, FEC, CHOP, EPOCH, Topotecan | 852 | Proportion of patients experiencing FN |
18 | Romieu et al. [33] | 2007 | BC | FEC | 60 | Incidence of neutropenic events |
19 | Vogel et al. [34] | 2005 | BC | Docetaxel | 928 | Percentage of patients developing FN |
20 | Grigg et al. [35] | 2003 | NHL | CHOP | 50 | Duration of grade 4 neutropenia |
21 | Vose et al. [36] | 2003 | ML | ESHAP | 66 | Incidence of grade 4 FN |
22 | Green et al. [37] | 2003 | BC | DA | 157 | Incidence of Grade 4 neutropenia |
23 | Holmes et al. [38] | 2002 | BC | DA | 310 | Absolute neutrophil count |
24 | Holmes et al. [39] | 2002 | BC | DA | 154 | Incidence of Grade 4 neutropenia in cycle 1 |
25 | Johnston et al. [40] | 2000 | NSCLC | Carboplatin and Paclitaxel | 13 | Serum concentrations |